Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Pfizer (NY:PFE)

23.87 -0.99 (-3.98%)
Official Closing Price Updated: 7:00 PM EDT, Sep 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises
Global psychedelic drugs market to reach $10.2 billion by 2028, driven by mental health needs and evolving regulatory support. 
Via Benzinga
What Lies In Store For Healthcare ETFs In Q3 Earnings?
The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited. 
Via Talk Markets
Topics ETFs
These 7 Blunt Words Just Opened a Can of Worms For Pfizer's Stock
The company's problems are no longer deniable. 
Via The Motley Fool
3 Magnificent S&P 500 Dividend Stocks Down 43%, 20%, and 53% to Buy and Hold Forever
The market is overlooking the bigger picture for these three names. That means opportunity for you. 
Via The Motley Fool
Topics Stocks
3 Spooky Signs That You're About to Lose Your Money on a Healthcare Stock Investment
Knowing these will help you avoid making suboptimal investing decisions. 
Via The Motley Fool
Key Takeaways From Pfizer Analyst Ratings
 
Via Benzinga
A Closer Look at Pfizer's Options Market Dynamics
 
Via Benzinga
Pfizer, Live Nation Entertainment And More On CNBC's 'Final Trades'
Pfizer shares fell 0.8% to close at $28.64 during Thursday's session. Live Nation Entertainment shares gained 1.5% to close at $116.45. 
Via Benzinga
Got $1,000? 2 Healthcare Stocks to Buy and Hold Forever.
These two stocks have moved in different directions this year, but that shouldn't mean much to long-term investors. 
Via The Motley Fool
3 Sweet Dividend Stocks to Treat Your Portfolio With This Halloween
There are more reasons to buy these stocks besides their high payouts. 
Via The Motley Fool
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for millions at risk of serious disease. 
Via Benzinga
CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines
The CDC recommends expanding pneumococcal vaccine eligibility to adults aged 50 and above, impacting disease prevention with Pfizer and Merck's vaccines. 
Via Benzinga
5 High-Yield Dividend Stocks to Buy Without Hesitation
These five dividend powerhouses offer yields above 4%. 
Via The Motley Fool
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition. 
Via Benzinga
Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older
From Pfizer Inc.
Via Business Wire
FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years
Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals to safeguard infants from birth. 
Via Benzinga
The Best Pharmaceutical Stock to Invest $1,000 in Right Now
Its cheap valuation, strong growth prospects, and massive dividend make it ripe for outsize investment returns. 
Via The Motley Fool
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
From Pfizer Inc.
Via Business Wire
Activist Investor Starboard Slams Pfizer for Underperforming R&D And Overpaying for Acquisitions
Starboard Value criticizes Pfizer's leadership for underperformance, citing a 50% stock decline and missed growth targets since the COVID-19 boom. 
Via Benzinga
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?
Viking Therapeutics (VKTX) set to report Q3 earnings amid high expectations, thanks to promising weight-loss drug candidate. Stock up 240% YTD. 
Via Benzinga
Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises
The activist investor says Pfizer has underperformed its peers and the broader market since 2019. 
Via Investor's Business Daily
Do Billionaires Israel Englander and Ken Griffin Know Something? Each Just Bought This Plagued Value Stock.
Hedge funds managed by Israel Englander and Ken Griffin both scooped up shares in a troubled pharmaceutical stock last quarter. 
Via The Motley Fool
Nvidia Among Five Best S&P 500 Stocks Today
Pfizer spinoff Kenvue led the S&P 500 on Monday. Nvidia was close behind. 
Via Investor's Business Daily
Topics Stocks
Three AI Stocks That Could Beat Nvidia After Today
Nvidia has returned 700% during the Age of AI, but smaller companies may have more room to run. Pfizer, Tesla, and Kroger are potential AI stocks. 
Via Benzinga
Topics Artificial Intelligence
1 Ultra-High-Yield Healthcare Stock to Buy Hand Over Fist and 1 to Avoid
Income investors have both good and not-so-good options in the healthcare sector. 
Via The Motley Fool
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Yes, bargains can still be found in the stock market. 
Via The Motley Fool
3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now
These stocks could deliver big over the long term. 
Via The Motley Fool
Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology
Northwestern University has filed a lawsuit against Moderna, alleging the company used its patented lipid nanoparticle technology without permission in the development of its COVID-19 vaccines. 
Via Benzinga
Topics Lawsuit
Guggenheim's Longstanding Pfizer Ties Tested Amid Starboard Battle
Guggenheim finds itself in the middle of a battle between Pfizer and Starboard Value as activist investors push for change amid declining stock performance and costly acquisitions. 
Via Benzinga
Why I'm Considering Leaning Heavily Into Pfizer
Pfizer's high dividend yield and robust pipeline could offer significant returns for patient investors. 
Via The Motley Fool
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.